{"pmid":32420612,"title":"COVID-19-associated immune thrombocytopenia.","text":["COVID-19-associated immune thrombocytopenia.","Thrombocytopenia is a risk factor for increased morbidity and mortality in patients with the new severe acute respiratory syndrome corona virus, SARS-CoV-2 infection (COVID-19 infection).(1) Thrombocytopenia in COVID-19 patients may be caused by disseminated intravascular coagulation (DIC), sepsis or drug-induced. Recently a single case report suggested immune thrombocytopenia (ITP) may be associated with COVID-19 infection.(2) ITP is a rare autoimmune disease characterized by a platelet count < 100x10(9) /L, leading to an increased bleeding risk.(3) Several risk factors have been described for ITP including environmental (e.g. infection, malignancy and drugs) and genetic predisposition.(4) We report here the first case series of three patients with ITP associated with COVID-19 infection.","Br J Haematol","Bomhof, G","Mutsaers, P G N J","Leebeek, F W G","Te Boekhorst, P A W","Hofland, J","Croles, F N","Jansen, A J G","32420612"],"abstract":["Thrombocytopenia is a risk factor for increased morbidity and mortality in patients with the new severe acute respiratory syndrome corona virus, SARS-CoV-2 infection (COVID-19 infection).(1) Thrombocytopenia in COVID-19 patients may be caused by disseminated intravascular coagulation (DIC), sepsis or drug-induced. Recently a single case report suggested immune thrombocytopenia (ITP) may be associated with COVID-19 infection.(2) ITP is a rare autoimmune disease characterized by a platelet count < 100x10(9) /L, leading to an increased bleeding risk.(3) Several risk factors have been described for ITP including environmental (e.g. infection, malignancy and drugs) and genetic predisposition.(4) We report here the first case series of three patients with ITP associated with COVID-19 infection."],"journal":"Br J Haematol","authors":["Bomhof, G","Mutsaers, P G N J","Leebeek, F W G","Te Boekhorst, P A W","Hofland, J","Croles, F N","Jansen, A J G"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32420612","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/bjh.16850","locations":["Thrombocytopenia","Thrombocytopenia"],"topics":["Case Report"],"weight":1,"_version_":1667254896710123520,"score":9.490897,"similar":[{"pmid":32374026,"title":"Practical guidance for the management of adults with Immune Thrombocytopenia during the COVID-19 pandemic.","text":["Practical guidance for the management of adults with Immune Thrombocytopenia during the COVID-19 pandemic.","This document aims to provide practical guidance for the assessment and management of patients with thrombocytopenia, with a particular focus on Immune Thrombocytopenia (ITP) during the COVID-19 pandemic. The intention is to support clinicians and, although recommendations have been provided, it is not a formal guideline. Nor is there sufficient evidence base to conclude that alternative approaches to treatment are incorrect. Instead, it is a consensus written by clinicians with an interest in ITP or coagulation disorders and reviewed by members of the UK ITP forum.","Br J Haematol","Pavord, S","Thachil, J","Hunt, B","Murphy, M","Lowe, G","Laffan, M","Makris, M","Newland, A","Provan, D","Grainger, J","Hill, Q","32374026"],"abstract":["This document aims to provide practical guidance for the assessment and management of patients with thrombocytopenia, with a particular focus on Immune Thrombocytopenia (ITP) during the COVID-19 pandemic. The intention is to support clinicians and, although recommendations have been provided, it is not a formal guideline. Nor is there sufficient evidence base to conclude that alternative approaches to treatment are incorrect. Instead, it is a consensus written by clinicians with an interest in ITP or coagulation disorders and reviewed by members of the UK ITP forum."],"journal":"Br J Haematol","authors":["Pavord, S","Thachil, J","Hunt, B","Murphy, M","Lowe, G","Laffan, M","Makris, M","Newland, A","Provan, D","Grainger, J","Hill, Q"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32374026","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/bjh.16775","locations":["thrombocytopenia","GBR"],"countries":["United Kingdom"],"countries_codes":["GBR|United Kingdom"],"topics":["Prevention"],"weight":1,"_version_":1666138496463536128,"score":385.09116},{"pmid":32420629,"title":"Evans syndrome in a patient with COVID-19.","text":["Evans syndrome in a patient with COVID-19.","Evans syndrome (ES) is a rare condition characterized by the combination of autoimmune hemolytic anemia and immune thrombocytopenia (ITP). While the precise pathophysiology is not entirely understood, it is believed that dysregulation of the immune system is a primary contributor to the condition. ES has been observed in viral infections including hepatitis C, cytomegalovirus, varicella-zoster, and Epstein-Barr viruses (1-4). Initial cases of coronavirus disease 2019 (COVID-19) were first described in early December 2019 and has now spread to a global pandemic. While knowledge about COVID-19 continues to evolve, clinicians have reported hematologic complications associated with the virus.","Br J Haematol","Li, Monica","Nguyen, Charles B","Yeung, Zachary","Sanchez, Katherine","Rosen, Daniel","Bushan, Sita","32420629"],"abstract":["Evans syndrome (ES) is a rare condition characterized by the combination of autoimmune hemolytic anemia and immune thrombocytopenia (ITP). While the precise pathophysiology is not entirely understood, it is believed that dysregulation of the immune system is a primary contributor to the condition. ES has been observed in viral infections including hepatitis C, cytomegalovirus, varicella-zoster, and Epstein-Barr viruses (1-4). Initial cases of coronavirus disease 2019 (COVID-19) were first described in early December 2019 and has now spread to a global pandemic. While knowledge about COVID-19 continues to evolve, clinicians have reported hematologic complications associated with the virus."],"journal":"Br J Haematol","authors":["Li, Monica","Nguyen, Charles B","Yeung, Zachary","Sanchez, Katherine","Rosen, Daniel","Bushan, Sita"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32420629","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/bjh.16846","locations":["Evans"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Case Report"],"weight":1,"_version_":1667159284511670272,"score":327.7863},{"pmid":32456506,"title":"Hemostatic laboratory derangements in COVID-19 with a focus on platelet count.","text":["Hemostatic laboratory derangements in COVID-19 with a focus on platelet count.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the coronavirus disease in 2019 (COVID-19) which rapidly evolved from an outbreak in Wuhan, China into a pandemic that has resulted in over millions of infections and over hundreds of thousands of mortalities worldwide. Various coagulopathies have been reported in association with COVID-19, including disseminated intravascular coagulation (DIC), sepsis-induced coagulopathy (SIC), local microthrombi, venous thromboembolism (VTE), arterial thrombotic complications, and thrombo-inflammation. There is a plethora of publications and conflicting data on hematological and hemostatic derangements in COVID-19 with some data suggesting the link to disease progress, severity and/or mortality. There is also growing evidence of potentially useful clinical biomarkers to predict COVID-19 progression and disease outcomes. Of those, a link between thrombocytopenia and COVID-19 severity or mortality was suggested. In this opinion report, we examine the published evidence of hematological and hemostatic laboratory derangements in COVID-19 and the interrelated SARS-CoV-2 induced inflammation, with a focussed discussion on platelet count alterations. We explore whether thrombocytopenia could be a potential disease biomarker and we provide recommendations for future studies in this regard.","Platelets","Amgalan, Ariunzaya","Othman, Maha","32456506"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the coronavirus disease in 2019 (COVID-19) which rapidly evolved from an outbreak in Wuhan, China into a pandemic that has resulted in over millions of infections and over hundreds of thousands of mortalities worldwide. Various coagulopathies have been reported in association with COVID-19, including disseminated intravascular coagulation (DIC), sepsis-induced coagulopathy (SIC), local microthrombi, venous thromboembolism (VTE), arterial thrombotic complications, and thrombo-inflammation. There is a plethora of publications and conflicting data on hematological and hemostatic derangements in COVID-19 with some data suggesting the link to disease progress, severity and/or mortality. There is also growing evidence of potentially useful clinical biomarkers to predict COVID-19 progression and disease outcomes. Of those, a link between thrombocytopenia and COVID-19 severity or mortality was suggested. In this opinion report, we examine the published evidence of hematological and hemostatic laboratory derangements in COVID-19 and the interrelated SARS-CoV-2 induced inflammation, with a focussed discussion on platelet count alterations. We explore whether thrombocytopenia could be a potential disease biomarker and we provide recommendations for future studies in this regard."],"journal":"Platelets","authors":["Amgalan, Ariunzaya","Othman, Maha"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32456506","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1080/09537104.2020.1768523","keywords":["covid","sars-cov-2","platelets","thrombocytopenia","thromboinflammation"],"locations":["Wuhan","China","thrombocytopenia","thrombocytopenia"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1668141322605690881,"score":219.35156},{"pmid":32483524,"pmcid":"PMC7255984","title":"Isolated severe thrombocytopenia in a patient with COVID-19: A case report.","text":["Isolated severe thrombocytopenia in a patient with COVID-19: A case report.","COVID-19 is known to cause serious respiratory symptoms and involvement of other body systems such as hematopoietic, neurological and the immune system. In this report, we described a case of a COVID-19 patient who presented with no pulmonary involvement but severe thrombocytopenia. She suffered from headache and malaise with no respiratory symptoms, fever or chills. Chest radiological imaging was unremarkable but, the laboratory results showed significant thrombocytopenia associated with relatively decreased lymphocytes. Based on her high-risk work environment, a reverse transcription polymerase chain reaction (RT-PCR) test was performed and SARS-CoV-2 RNA was detected in the nasopharyngeal swab. Complete blood count (CBC) of patient was re-checked during admission and platelet count showed rising trend up to normal levels. A narrow diagnostic approach where only febrile patients with pulmonary symptoms are evaluated for a COVID-19 diagnosis will result in many missed diagnoses; so it is important that physicians are familiar with atypical and rare presentations of COVID-19, such as isolated thrombocytopenia.","IDCases","Sadr, Sara","SeyedAlinaghi, SeyedAhmad","Ghiasvand, Fereshteh","Hassan Nezhad, Malihe","Javadian, Nina","Hossienzade, Roghieh","Jafari, Fatemeh","32483524"],"abstract":["COVID-19 is known to cause serious respiratory symptoms and involvement of other body systems such as hematopoietic, neurological and the immune system. In this report, we described a case of a COVID-19 patient who presented with no pulmonary involvement but severe thrombocytopenia. She suffered from headache and malaise with no respiratory symptoms, fever or chills. Chest radiological imaging was unremarkable but, the laboratory results showed significant thrombocytopenia associated with relatively decreased lymphocytes. Based on her high-risk work environment, a reverse transcription polymerase chain reaction (RT-PCR) test was performed and SARS-CoV-2 RNA was detected in the nasopharyngeal swab. Complete blood count (CBC) of patient was re-checked during admission and platelet count showed rising trend up to normal levels. A narrow diagnostic approach where only febrile patients with pulmonary symptoms are evaluated for a COVID-19 diagnosis will result in many missed diagnoses; so it is important that physicians are familiar with atypical and rare presentations of COVID-19, such as isolated thrombocytopenia."],"journal":"IDCases","authors":["Sadr, Sara","SeyedAlinaghi, SeyedAhmad","Ghiasvand, Fereshteh","Hassan Nezhad, Malihe","Javadian, Nina","Hossienzade, Roghieh","Jafari, Fatemeh"],"date":"2020-06-03T11:00:00Z","year":2020,"_id":"32483524","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.idcr.2020.e00820","keywords":["coronavirus disease 2019 (covid-19)","lymphopenia","severe acute respiratory syndrome coronavirus 2 (sars-cov-2)","thrombocytopenia"],"topics":["Case Report"],"weight":1,"_version_":1668704334431387648,"score":203.09549},{"pmid":32302435,"title":"Thrombocytopenia and its association with mortality in patients with COVID-19.","text":["Thrombocytopenia and its association with mortality in patients with COVID-19.","BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes novel coronavirus disease 2019 (COVID-19), is spreading rapidly around the world. Thrombocytopenia in patients with COVID-19 has not been fully studied. OBJECTIVE: To describe thrombocytopenia in patients with COVID-19. METHODS: For each of 1476 consecutive patients with COVID-19 from Jinyintan Hospital, Wuhan, China, nadir platelet count during hospitalization was retrospectively collected and categorized into (0, 50], (50, 100], (100-150], or (150-) groups after taking the unit (x10(9) /L) away from the report of nadir platelet count. Nadir platelet counts and in-hospital mortality were analyzed. RESULTS: Among all patients, 238 (16.1%) patients were deceased and 306 (20.7%) had thrombocytopenia. Compared with survivors, non-survivors were older, were more likely to have thrombocytopenia, and had lower nadir platelet counts. The in-hospital mortality was 92.1%, 61.2%, 17.5%, and 4.7% for (0, 50], (50, 100], (100-150], and (150-) groups, respectively. With (150-) as the reference, nadir platelet counts of (100-150], (50, 100], and (0, 50] groups had a relative risk of 3.42 (95% confidence interval [CI] 2.36-4.96), 9.99 (95% CI 7.16-13.94), and 13.68 (95% CI 9.89-18.92), respectively. CONCLUSIONS: Thrombocytopenia is common in patients with COVID-19, and it is associated with increased risk of in-hospital mortality. The lower the platelet count, the higher the mortality becomes.","J Thromb Haemost","Yang, Xiaobo","Yang, Qingyu","Wang, Yaxin","Wu, Yongran","Xu, Jiqian","Yu, Yuan","Shang, You","32302435"],"abstract":["BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes novel coronavirus disease 2019 (COVID-19), is spreading rapidly around the world. Thrombocytopenia in patients with COVID-19 has not been fully studied. OBJECTIVE: To describe thrombocytopenia in patients with COVID-19. METHODS: For each of 1476 consecutive patients with COVID-19 from Jinyintan Hospital, Wuhan, China, nadir platelet count during hospitalization was retrospectively collected and categorized into (0, 50], (50, 100], (100-150], or (150-) groups after taking the unit (x10(9) /L) away from the report of nadir platelet count. Nadir platelet counts and in-hospital mortality were analyzed. RESULTS: Among all patients, 238 (16.1%) patients were deceased and 306 (20.7%) had thrombocytopenia. Compared with survivors, non-survivors were older, were more likely to have thrombocytopenia, and had lower nadir platelet counts. The in-hospital mortality was 92.1%, 61.2%, 17.5%, and 4.7% for (0, 50], (50, 100], (100-150], and (150-) groups, respectively. With (150-) as the reference, nadir platelet counts of (100-150], (50, 100], and (0, 50] groups had a relative risk of 3.42 (95% confidence interval [CI] 2.36-4.96), 9.99 (95% CI 7.16-13.94), and 13.68 (95% CI 9.89-18.92), respectively. CONCLUSIONS: Thrombocytopenia is common in patients with COVID-19, and it is associated with increased risk of in-hospital mortality. The lower the platelet count, the higher the mortality becomes."],"journal":"J Thromb Haemost","authors":["Yang, Xiaobo","Yang, Qingyu","Wang, Yaxin","Wu, Yongran","Xu, Jiqian","Yu, Yuan","Shang, You"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32302435","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jth.14848","keywords":["covid-19","sars-cov-2","generalized linear model","mortality","thrombocytopenia"],"locations":["Thrombocytopenia","Jinyintan Hospital","Wuhan","China","thrombocytopenia","thrombocytopenia","Thrombocytopenia","Thrombocytopenia"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1666138494801543172,"score":201.17773}]}